Ask My Investor AI
Public company · Frankfurt Stock ExchangePublished company research
SHL

Official issuer materials identify Siemens Healthineers AG as a Frankfurt-listed public company reporting in euros; there is no U.S. SEC CIK in this profile.

Siemens Healthineers AG

Siemens Healthineers has direct nuclear-medicine capability through PET/CT, SPECT/CT, PET/MR and a radiopharmaceutical network created from PETNET Solutions and AdAcAp Molecular Imaging. The issuer reports 60 PET-radiopharmaceutical facilities in nine countries and more than 100,000 sterile batches per year. Group and segment results do not separately disclose Radiopharma or molecular-imaging revenue, so theme-specific economics and licensed valuation remain unresolved and the subject is NOT_READY.

Ask follow-up research
Reviewed company research · researched 2026-07-29 · not an individual investment recommendation
Listing
public
Ticker
SHL
Exchange
Frankfurt Stock Exchange
HQ
Germany
Currency
EUR
SEC CIK
Non-SEC filer
Investment case

How this company captures the theme economics

Competitive position

The combination of a large molecular-imaging installed base and a 60-facility PET-radiopharmacy network creates an integrated equipment, tracer and workflow position across the U.S. and Europe. Qualification, cyclotron density, short-half-life logistics and regulated sterile manufacturing are meaningful barriers, but the business competes inside a much larger med-tech group and its standalone economics are undisclosed.

Scarce assets

Sixty PET-radiopharmaceutical facilities in nine countries, 47 cyclotron-powered U.S. radiopharmacies, 13 European manufacturing sites, regulated sterile-manufacturing processes, tracer distribution logistics and a global molecular-imaging installed base.

Products, segments, and customers

The group reports Imaging, Diagnostics, Varian and Advanced Therapies. Medical-isotope exposure spans Biograph PET/CT and PET/MR, Symbia SPECT/CT, theranostics workflows and the Radiopharma network that manufactures and distributes PET tracers and CDMO products.

Theme capture

Siemens Healthineers captures nuclear-medicine adoption through equipment placements, service, tracer manufacturing and distribution. The operating role is directly evidenced, but Radiopharma and molecular-imaging revenue and profit are not separated from broader reported segments.

Conditions

What must be true

  1. The 60-facility Radiopharma network must convert growing PET and theranostics demand into sustained volumes and attractive economics.
  2. Molecular-imaging systems and tracer distribution must remain differentiated as competing equipment and radiopharmacy networks expand.

Identifiable catalysts

  • Growth in PET/SPECT installations and theranostics workflows.
  • Commercial expansion of the combined PETNET and AdAcAp Radiopharma network.
  • Future disclosure of Radiopharma or molecular-imaging revenue, orders, batches, utilization or margins.
Theme materiality

2 mapped themes

Exposure statements are evidence-qualified. Materiality is only claimed where disclosure supports it.

PET/CT, SPECT/CT and PET/MR equipment plus PET-radiopharmaceutical manufacturing, distribution and CDMO services.

Medical isotopes and radiopharmaceutical logistics

Direct operating capability with unresolved financial magnitude. The issuer states that its Radiopharma business operates 60 facilities in nine countries and produces more than 100,000 sterile PET-radiopharmaceutical batches annually, while its molecular-imaging portfolio supports PET, SPECT and theranostics workflows.

Evidence
Official issuer pages directly support the network scale and product role. Q2 FY2026 reporting provides current group and segment context but does not isolate Radiopharma or molecular-imaging economics.
Materiality
not assessed — Radiopharma and molecular imaging are embedded within broader reported businesses; no revenue, profit, order or utilization disclosure reviewed permits theme-specific financial sizing.
Women's imaging through the Mammomat mammography portfolio within the broader imaging business.

Women's health formalization

Direct product exposure with no separately disclosed women's-health economics in the sources reviewed.

Evidence
This bounded pass did not re-review the women's-health mapping; it remains fail-closed on standalone economics.
Materiality
not assessed — Women's-health revenue and profit are not separately disclosed.
Financial evidence

Official public disclosures

Reference period: FY2025 and Q2 FY2026.

  • Group comparable revenue growth3.1%
    Q2 FY2026[1]
  • Adjusted EBIT margin14.7%
    Q2 FY2026[1]
  • Adjusted basic EPSEUR 0.53
    Q2 FY2026[1]
  • Free cash flowEUR 389M
    Q2 FY2026[1]
  • Imaging comparable revenue growth and adjusted EBIT margin6.1% growth; 22.4% margin
    Q2 FY2026[1]
  • Group revenueapproximately EUR 23.4B
    FY2025[1]

Limitation: Current group and segment performance is official, but Radiopharma and molecular-imaging revenue, profit, orders and utilization are not separately disclosed. Licensed current valuation is unavailable.

Risks

Material risks and break conditions

Material risks

  • Radiopharma network utilization and pricing may weaken if PET-tracer supply expands faster than demand.
  • The short-half-life distribution model carries manufacturing, regulatory, quality and logistics risk.
  • Theme exposure may remain too small or too aggregated within the group to drive equity outcomes.

Thesis-break conditions

  • The combined Radiopharma network fails to grow batch volume or loses third-party CDMO programs.
  • PET/SPECT equipment growth decouples from radiopharmaceutical adoption.
  • Future disclosure shows immaterial or structurally weak Radiopharma economics.
Investability conclusion

Where the evidence lands

NOT_READY. Official sources establish public identity, current group results, a 60-facility Radiopharma network and molecular-imaging capability. Standalone theme economics, licensed valuation and human reviewer acceptance remain unavailable.

Next diligence

  1. Obtain Radiopharma revenue, batch volume growth, utilization, margin and third-party CDMO mix.
  2. Separate molecular-imaging orders and service economics from broader Imaging results.
  3. Add licensed current valuation before any price or entry judgment.
Source ledger

Identity and evidence sources

Identity was verified against official issuer, filing, exchange, or regulator sources where available.

  1. Siemens Healthineers Q2 FY2026 resultsSiemens Healthineers AG · primary · published 2026-05-07 · accessed 2026-07-29
  2. PETNET Solutions and Advanced Accelerator Applications rebranded as Siemens HealthineersSiemens Healthineers AG · primary · published 2025-11-18 · accessed 2026-07-29
  3. Molecular Imaging and RadiopharmaSiemens Healthineers AG · primary · published 2026-05-30 · accessed 2026-07-29